Updated September 2026Starting dose only at $149PlushCare review
The advertised cash-pay figure buys the 0.25 mg starting dose, and every maintenance dose is priced above it.
The verdict
PlushCare advertises compounded semaglutide at $149 a month cash-pay, and that figure covers the 0.25 mg starting dose only. Tirzepatide is $399. Insurance is accepted on a separate basis from either.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- States
- 50
- From
- $149/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
PlushCare sells compounded semaglutide and compounded tirzepatide as weekly injections, across fifty states. The two cash-pay figures read $149 and $399 a month on August 15, 2026. The $149 is stated to buy the 0.25 mg starting dose. Insurance is accepted as a separate route to treatment.
Who writes the prescription, and what do they see?
Treatment runs through a clinician visit rather than a form alone, and insurance is billed where it applies. That is a different model from a flat-fee compounding seller with no visit in it. What the visit covers, and how often it repeats, is not published. The two routes are priced separately and a reader chooses one at intake.
Care is arranged remotely and the prescription follows the visit. The cash-pay figure and the insurance route answer different questions for different readers. A reader with coverage is comparing a copay against $149 rather than comparing sellers. A reader without coverage is comparing $149 against a market where most rates are flat.
What happens when the dose goes up?
This is the seller's weak point and it is stated plainly. $149 buys 0.25 mg, and 0.25 mg is a four-week starting dose for almost everyone. The maintenance doses cost more, and what each step costs is not published beside the entry figure. A reader planning a year should treat $149 as the first month rather than the standing rate.
What the price includes
$149 is real and it is narrow. Sellers charging a flat $199 hold that figure at 2.4 mg, where $149 does not. The tirzepatide figure of $399 carries no dose qualification beside it at all. Insurance may change either figure and is settled case by case rather than published.
What it claims, and what it cites
Both products are compounded, so a pharmacy prepares them and no regulator reviews the finished vial. The published weight-change results for semaglutide came from the approved product at maintenance doses, not at 0.25 mg. A starting dose is a titration step rather than a treatment dose. What four weeks at 0.25 mg produces on its own was not measured as an endpoint.
Where it holds up, and where it does not
- Strength: Says what the entry figure buys
- Strength: Insurance accepted as a separate route
- Strength: Prescription follows a clinician visit
- Limitation: Maintenance doses priced above $149
- Limitation: Step prices not published up front
- Limitation: Tirzepatide sits high for a compounded rate
What the evidence says about this kind of treatment
The assessment above is about PlushCare. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one.
- Wrong for
- A reader budgeting a year at one rate, because the advertised figure covers 0.25 mg and every dose above it is priced higher.
How PlushCare compares
| Seller | Who it suits | Go |
|---|---|---|
 Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | See Liberty → |
 Pallas Health | A reader who expects to stay past the first quarter and wants provider check-ins inside the price rather than billed against each visit. | See Pallas Health → |
| Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | See Harper Meds → |
More GLP-1 telehealth sellers reviews: Synergy RxAlan MedsAlloyApex MDAVARA RxBayan Health
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Is $149 what a maintenance dose costs?
- No. PlushCare states that the $149 cash-pay figure buys the 0.25 mg starting dose, and that every maintenance dose is priced higher. The step prices are not published beside it.
- How long does anyone stay at 0.25 mg?
- The approved semaglutide schedule holds 0.25 mg for four weeks before the first increase. A reader on that schedule is past the advertised figure by month two.
- Does insurance change the price?
- Insurance is accepted on a separate basis from the cash-pay figure, and what it leaves a patient to pay is settled case by case rather than published.
- Is PlushCare expensive compared with other GLP-1 telehealth sellers?
- PlushCare publishes a starting figure of $149/mo. Across the 32 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $139, which puts PlushCare above the median. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.